Armin Ghobadi, MD, on Assessing CAR-T Cell Combination Therapies

“CAR T is just the start of a big wave. I use the analogy of penicillin when it was invented. It’s a big step but we have ways to go. The only difference here is that we have really advanced technology and tools that we can use to go forward significantly faster. And hopefully in the next few years, we're going to see more and more of those combinations that enhance efficacy and decrease toxicities and cure more patients.”

NeoImmune Tech’s long-acting human IL-7, NT-I7 (efineptakin alfa), was well-tolerated in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL) and increased absolute lymphocyte counts (ALC) and chimeric antigen receptor (CAR) T-cell expansion when administered after tisagenlecleucel (tisa-cel; Kymriah). These data, from a phase 1b study (NCT05075603), were presented by Armin Ghobadi, MD, associate professor medicine, Siteman Cancer Center, Washington University in St. Louis School of Medicine at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana

CGTLive spoke to Ghobadi to learn more about the potential of combining CAR T-cell therapies with other factors or therapies to improve their efficacy. He discussed further research he would like to see conducted with the therapies as well as other potential combinations to assess.

Click here to read more coverage of the 2022 ASH meeting.

REFERENCE

Ghobadi A, Budde EL, Galal A, et al. A phase 1b dose expansion study evaluating safety, preliminary anti-tumor activity, and accelerated T cell reconstitution with NT-I7 (Efineptakin Alfa), a long-acting human IL-7, administered following tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans, Louisiana.